PLRZ
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock trades at a discount to book value, but book value is eroding due to negative returns.
- P/B ratio of 0.84
- No P/E or PEG available due to lack of earnings
- No Graham Number available
No data suggests a pivot to profitability or commercialization of biotech assets.
- No reported revenue growth
- No earnings growth
- Negative ROE
Historical performance is indicative of a failing business model or extreme dilution.
- Short-term 6-month bounce
- 99.5% loss over 5 years
- 98% loss over 1 year
High liquidity is the only saving grace, but it is not being converted into operational growth.
- Exceptional current and quick ratios
- Piotroski F-Score 2/9
- Negative ROA
Company is in no position to return capital to shareholders.
- No dividend yield
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PLRZ and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PLRZ
Polyrizon Ltd.
Primary
|
-99.5% | -99.5% | -98.0% | +70.4% | -19.6% | +1.8% |
|
HBIO
Harvard Bioscience, Inc.
Peer
|
-93.5% | -91.5% | +10.5% | +2.6% | -15.5% | -17.1% |
|
AIDX
20/20 Biolabs, Inc.
Peer
|
-92.0% | -92.0% | -92.0% | -92.0% | -32.8% | +1.6% |
|
IINN
Inspira Technologies Oxy B.H.N. Ltd.
Peer
|
-91.0% | -65.5% | -31.4% | -62.4% | -26.0% | -11.8% |
|
CUE
Cue Biopharma, Inc.
Peer
|
-98.5% | -94.2% | -69.9% | -75.0% | -37.5% | -18.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PLRZ
Polyrizon Ltd.
|
BEARISH | $19.5M | - | -25.4% | -% | $10.94 | |
|
HBIO
Harvard Bioscience, Inc.
|
BEARISH | $19.27M | - | -147.1% | -65.5% | $4.31 | Compare |
|
AIDX
20/20 Biolabs, Inc.
|
BEARISH | $19.95M | - | -503.1% | -182.8% | $1.91 | Compare |
|
IINN
Inspira Technologies Oxy...
|
BEARISH | $18.52M | - | -397.9% | -% | $0.42 | Compare |
|
CUE
Cue Biopharma, Inc.
|
NEUTRAL | $18.38M | - | -121.1% | -96.9% | $0.19 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning PLRZ from our newsroom.